Aug 11, 2026 06:57AM
Aug 10, 2026 07:00AM
Jul 16, 2026 06:47AM
Jul 15, 2026 07:00AM
Jul 15, 2026 07:00AM
May 5, 2026 04:20AM
Apr 28, 2026 09:13AM Axsome Therapeutics (AXSM) PT Lowered to $228 at Mizuho
Apr 10, 2026 09:31AM
Apr 1, 2026 12:10PM
Mar 25, 2026 06:07AM
Mar 13, 2026 06:02AM
Feb 24, 2026 09:04AM
Feb 24, 2026 05:40AM
Feb 23, 2026 12:32PM Truist Securities Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Feb 23, 2026 12:17PM
Feb 23, 2026 07:00AM
Jan 13, 2026 04:52AM
Jan 8, 2026 03:37AM
Jan 5, 2026 06:40AM
Jan 2, 2026 08:53AM
Jan 2, 2026 06:23AM Guggenheim Reiterates Buy Rating on Axsome Therapeutics (AXSM)
Dec 31, 2025 01:54PM
Dec 31, 2025 01:20PM
Dec 31, 2025 01:19PM
Dec 31, 2025 12:42PM
Dec 31, 2025 08:25AM
Dec 31, 2025 08:24AM
Dec 31, 2025 07:00AM Axsome gets FDA priority review for Alzheimer's agitation drug
Dec 31, 2025 07:00AM
Dec 31, 2025 06:55AM
Dec 31, 2025 06:55AM
Jan 13, 2025 12:50PM
Dec 16, 2024 07:03AM
Nov 26, 2024 07:00AM
Nov 26, 2024 07:00AM Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy
Nov 12, 2024 07:00AM
Sep 5, 2024 06:48AM
Sep 4, 2024 07:01AM
Sep 4, 2024 07:00AM
Apr 30, 2024 09:00PM
Apr 17, 2024 09:00PM
Apr 12, 2024 02:30AM AXSOME ALERT: Bragar Eagel & Squire, P.C. is Investigating Axsome Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Apr 3, 2024 09:00PM
Mar 25, 2024 09:00PM
Mar 25, 2024 06:31AM
Mar 25, 2024 06:30AM
Aug 19, 2022 10:39AM
Jul 4, 2022 09:00PM
Jun 29, 2022 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against First High-School, Upstart, Oscar, and Axsome and Encourages Investors to Contact the Firm
Jun 24, 2022 09:00PM

15,744 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All